13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO , March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine... Read More

Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply Provides Annual Capacity of Over 1 Billion Oral Tablets Viking to Make... Read More

SAN DIEGO , March 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows: Leerink Partners Global Healthcare Conference 2025... Read More

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Underway Strong Year-End Cash Position of $903 Million SAN DIEGO , Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking")... Read More

Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO , Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2024 after the market close... Read More

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the... Read More

SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian , Ph.D., will deliver a corporate... Read More

Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary Endpoints Data Support VK2809's Best-in-Class Profile Highlighted by Robust Liver Fat Reductions, Histologic Results Demonstrating NASH/MASH Resolution and Fibrosis Improvement, and Promising... Read More

Results to be Featured in Oral Late Breaker Presentation SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the company's... Read More

Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 Study of Subcutaneous VK2735 Show Durable Effects and Support... Read More

SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences. Details of... Read More

Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO , Oct. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies... Read More

Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 Results of Phase 2b VOYAGE Study of VK2809 in NASH /MASH With Fibrosis Selected for Oral Presentation at AASLD Positive Phase 1b Results... Read More

Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday,... Read More

Reductions in Very Long-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Once Daily Dosing VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study SAN DIEGO , Oct. 9, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the... Read More

SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian , Ph.D., will be the featured speaker in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference. The conference will... Read More

Conference call scheduled for 4:30 p.m. ET today VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24 Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24 Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24 In Vivo Data From Novel Amylin Agonist Program... Read More

Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO , July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2024 after the market close on Wednesday,... Read More

Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO , June 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of... Read More

Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001) Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage Improvement in Fibrosis with No Worsening of NASH as Compared to 34% for Placebo (p<0.05) Up to 48% of VK2809-Treated Patients Achieved Both Resolution of NASH and a ≥1-Stage Improvement in Fibrosis as Compared to 20% for Placebo... Read More

SAN DIEGO , May 30, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. Details of the company's participation are as follows: 2024 Jefferies Global Healthcare Conference Details: Viking... Read More

Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From Baseline) at 13 Weeks; Shown to be Safe and Well-Tolerated Results From Phase 1 Trial of Oral VK2735 Demonstrated Promising Safety and Tolerability With Up to 3.3% Placebo-Adjusted Weight Loss (5.3% From Baseline) at 28 Days 52-Week... Read More

Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time SAN DIEGO , April 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday,... Read More

Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 Trial in Obesity Planned for 2H24 Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO , March 26, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company... Read More

SAN DIEGO , March 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 7,441,650 shares of its common stock at a price to the public of $85.00 per share, which included the exercise in... Read More

SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its underwritten public offering of 6,471,000 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds from the offering, before deducting... Read More

SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. Viking also intends to grant the underwriters a 30-day option to purchase up to an... Read More

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau Observed VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 95% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate... Read More

Conference call scheduled for 4:30 p.m. ET today Results for Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Expected in 1Q24 Histology Results for Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Expected in 1H24 Results for Phase 1 Trial of Oral VK2735 Expected in 1Q24 Strong Year-End Cash Position of $362 Million SAN DIEGO , Feb. 7, 2024 /PRNewswire/ -- Viking Therapeutics, Inc.... Read More

Conference Call Scheduled for Wednesday, February 7 at 4:30 p.m. Eastern Time SAN DIEGO , Jan. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2023 after the market close... Read More

Late Breaking Poster Presentation Reports New Results Demonstrating Robust Liver Fat Reductions Across Key Subgroups, Including Patients with Type 2 Diabetes and Among Those with F2 or F3 Fibrosis Presentation also Highlights Previously Reported Results Showing Successful Achievement of Study's Primary Endpoint, Statistically Significant Liver Fat Reductions from Baseline to Week 12 Among Patients Receiving VK2809 52-Week... Read More

SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences. Details of the company's participation are as follows: Truist Securities 2023 BioPharma Symposium Details: Viking... Read More

Conference call scheduled for 4:30 p.m. ET today Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Fully Enrolled; Results Expected 1H24 Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Ongoing; Histology Results Expected 1H24 Phase 1 Trial of Oral VK2735 Continues to Enroll; Results Expected 1Q24 Strong Quarter-End Cash Position of $376M SAN DIEGO , Oct. 25, 2023 /PRNewswire/ --... Read More

13-Week Study to Evaluate the Safety and Efficacy of VK2735 Dosed Weekly Trial Size Increased from 125 to 176 Patients Due to Elevated Demand SAN DIEGO , Oct. 23, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its... Read More

Conference Call Scheduled for Wednesday, October 25 at 4:30 p.m. Eastern Time SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2023 after the market close on Wednesday,... Read More

Presentation Highlights Previously Reported Weight Loss of up to 7.8% From Baseline as well as Significant Liver Fat, Plasma Lipid Reductions following 28 Days of Treatment with VK2735 SAN DIEGO , Oct. 17, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that... Read More

Presentation to Highlight VK2735's Preliminary Safety, Tolerability, and Pharmacodynamic Effects in Healthy Volunteers SAN DIEGO , Oct. 10, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that data from the company's Phase 1 single ascending dose (SAD) and... Read More

SAN DIEGO , Sept. 7, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. Details of the company's participation are as follows: H.C. Wainwright 25 th Annual Global Investment Conference... Read More

13-Week Study to Evaluate the Safety and Efficacy of VK2735 Dosed Weekly SAN DIEGO , Sept. 6, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like... Read More

Conference call scheduled for 4:30 p.m. ET today Reported Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH, Showing up to 55% Median Liver Fat Reduction; 52 Week Biopsy Results Expected 1H24 Phase 2 Study of Dual GLP-1/GIP Agonist VK2735 in Obesity Planned for 3Q23 Phase 1 Trial of Oral VK2735 Ongoing; Results Expected 4Q23 Strong Quarter-End Cash Position of $393M SAN... Read More

Conference Call Scheduled for Wednesday, July 26 at 4:30 p.m. Eastern Time SAN DIEGO , July 19, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2023 after the market close on Wednesday,... Read More

Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in Liver Fat from Baseline to Week 12 in Patients Receiving VK2809 as Compared to Placebo Up to 52% Mean Liver Fat Reduction Observed in VK2809-Treated Patients Up to 85% of Patients Experienced at Least a 30% Relative Reduction in Liver Fat Statistically Significant Reductions in LDL-C, Triglycerides, and Atherogenic Lipoproteins Observed... Read More

Conference call scheduled for 4:30 p.m. ET today Three Additional Data Announcements Expected in 2023 Completed Enrollment in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in 2Q 2023 Reported VK2735 Phase 1 Data Demonstrating Up to 6% Placebo-Adjusted Mean Weight Loss (7.8% from Baseline), Promising Safety and Tolerability Initiated Phase 1 Trial Evaluating Highly Differentiated Oral Formulation of... Read More

Conference Call Scheduled for Wednesday, April 26 at 4:30 p.m. Eastern Time SAN DIEGO , April 20, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the first quarter 2023, after the market close on Wednesday,... Read More

SAN DIEGO , April 11, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian , Ph.D., will deliver a corporate presentation as part of the 22 nd Annual Needham Healthcare Conference. The conference will take place April... Read More

SAN DIEGO , April 3, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per share, which includes the exercise in... Read More

SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its underwritten public offering of 17,242,000 shares of its common stock at a price to the public of $14.50 per share. Gross proceeds, before deducting underwriting... Read More

SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Viking also expects to grant to the underwriters of the offering a 30-day option to... Read More

Expands Potential Opportunities for VK2735 with Highly Differentiated Dosing Option Data Anticipated in 2H2023 SAN DIEGO , March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has initiated a Phase 1 clinical study to evaluate a novel oral... Read More

Up to 6.0% Placebo-Adjusted Mean Weight Loss (7.8% From Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study Phase 2 Trial in Obesity Planned for Mid-2023 SAN DIEGO , March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today... Read More

SAN DIEGO , March 7, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. Details of the company's participation are as follows: 35 th Annual Roth Conference Details: Brian Lian , Ph.D.,... Read More

Conference call scheduled for 4:30 p.m. ET today Data from Three Clinical Programs Expected in 2023 Enrollment Completed in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in 2Q 2023 Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Continues; Data Expected in 1Q 2023 SAN DIEGO , Feb. 8, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company... Read More

SAN DIEGO , Feb. 7, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian , Ph.D., will deliver a corporate presentation as part of the SVB Securities Global Biopharma Conference. The conference will take place February... Read More

Conference Call Scheduled for Wednesday, February 8 at 4:30 p.m. Eastern Time SAN DIEGO , Feb. 1, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2022, after the market close... Read More

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Range of VK2809 Doses for up to 52 Weeks; Data for Primary Endpoint Expected in First Half of 2023 SAN DIEGO , Jan. 9, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion... Read More